SCHEMBL3089875

SCHEMBL3089875

CS(=O)(=O)NCc1ccc(N2CCCCC2)c(N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.53
RAB9A P51151 2/20 0.50
KDM4E B2RXH2 5/20 0.48
NPC1 O15118 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
S100B P04271 1/20 0.48
GAA P10253 6/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089872 0.82 CSF1R (0.55) CSF1RKDM4ENPC1SMN1; SMN2GAA
SCHEMBL23850820 0.74 RAB9A (0.70) RAB9AKDM4ENPC1SMN1; SMN2NPSR1
SCHEMBL31587411 0.74 RAB9A (0.70) RAB9AKDM4ENPC1SMN1; SMN2NPSR1
SCHEMBL23043757 0.74 S100B (0.56) RAB9AKDM4ENPC1SMN1; SMN2NPSR1
SCHEMBL13542495 0.73 ALDH1A1 (0.60) RAB9AKDM4ENPC1SMN1; SMN2NPSR1
SCHEMBL358763 0.73 S100B (0.59) CSF1RRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL12837764 0.73 ALDH1A1 (0.60) RAB9AKDM4ENPC1SMN1; SMN2NPSR1
SCHEMBL13148112 0.71 CSF1R (1.00) CSF1R
SCHEMBL9980390 0.70 RAB9A (0.65) RAB9AKDM4ENPC1SMN1; SMN2NPSR1
SCHEMBL3083572 0.70 S100B (0.44) CSF1RRAB9AKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429603-B2 Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2008-09-30 US claimed
US-20050004112-A1 C-fms kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7429603-B2 Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed
US-20050004112-A1 C-fms kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885RAB9A 3062/4885KDM4E 1464/4885
US-20050004112-A1 C-fms kinase inhibitors FLT3, FGR, FER CSF1R 76/4885RAB9A 2748/4885KDM4E 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.